capecitabine

Type: Keyphrase

Name: capecitabine

First reported 20 hours ago - Updated 20 hours ago - 1 reports

Adherex urged to consider larger eniluracil trials

Adherex Technologies Inc. has received feedback from the U.S. Food and Drug Administration at an end-of-phase-2 meeting held yesterday. During the FDA meeting, Adherex reviewed the opportunity that eniluracil offers to metastatic breast cancer patients ... [Published Stockwatch - 20 hours ago]

Entities: eniluracil, Oncology, Adherex Technologies Inc, FDA Food & Drug Administration

First reported May 20 2013 - Updated May 20 2013 - 1 reports

ZELTIA SA: PharmaMar commences a Phase Ib trial with PM01183 in combination with Capecitabine

Zeltia SA : PharmaMar commences a Phase Ib trial with PM01183 in combination with CapecitabineZELTIA NEWS:PM01183 in combination with CapecitabineThe primary endpoint of the trial is to determine therecommended dose (RD) for PM01183 in combination with ... [Published 4 Traders - May 20 2013]

Entities: Zeltia SA, capecitabine, Phase I, Tumor, primary endpoint

First reported May 18 2013 - Updated May 18 2013 - 1 reports

How Do I Treat Patients with Locally Advanced Gastric Cancer?

Gastric cancer presents a daunting health problem globally, accounting for the second leading cause of cancer-related death worldwide. In the United States, more distal gastric cancers are declining in incidence, partly due to eradication of Helicobacter ... [Published Oncology Times - May 18 2013]

Entities: GASTRIC CANCER, Chemotherapy, Patient, gastrectomy, Radiation Therapy

First reported May 17 2013 - Updated May 17 2013 - 1 reports

Eisai Co Ltd

EISAI TO PRESENT NEW RESEARCH ON ONCOLOGY PRODUCTS AND PIPELINE AT 49TH ASCO ANNUAL MEETING

Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito, "Eisai") announced today that a series of abstracts highlighting new study results on Halaven$ (generic name: eribulin mesylate; non-taxane microtubule dynamics inhibitor) and lenvatinib ... [Published Noodls - May 17 2013]

Entities: Eisai Co Ltd, Oncology, Pipeline, Halaven

First reported May 17 2013 - Updated May 17 2013 - 1 reports

Study Findings from G. Bisagni et al Broaden Understanding of Breast Cancer

(NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Investigators publish new report on Breast Cancer. According to news reporting originating from Cremona, Italy, by NewsRx correspondents, research stated, "Therapeutic approach ... [Published NewsRX - May 17 2013]

Entities: Breast Cancer, bevacizumab, Cremona (Italy), capecitabine, maintenance therapy

First reported May 14 2013 - Updated May 15 2013 - 1 reports

Human medicines European Public Assessment Report (EPAR): Ecansya (previously Capecitabine Krka), capecitabine, Revision: 2, Authorised

[Published Pending EC decisions and European Public Assess ... - May 14 2013]

Entities: capecitabine, Krka

First reported May 06 2013 - Updated May 06 2013 - 1 reports

capecitabine

Human medicines European Public Assessment Report (EPAR): Capecitabine Teva, capecitabine, Revision: 1, Authorised

[Published Pending EC decisions and European Public Assess ... - May 06 2013]

Entities: capecitabine

First reported Apr 27 2013 - Updated Apr 27 2013 - 1 reports

EMA opinions: good news for Astellas, Roche and Vivus

The latest set of opinions from advisors to the sees five new medicines and two generics recommended for approval.First up, the agency's Committee for Human Medicinal Products (CHMP) has issued a positive recommendation on Astellas and Medivation's Xtandi ... [Published Pharma Times - Apr 27 2013]

Entities: Astellas Pharma Inc, Roche Holding AG, NUEDEXTA, chondrocyte, Quinidine

First reported Apr 26 2013 - Updated Apr 26 2013 - 1 reports

Pending EC decision: Capecitabine SUN, capecitabine, Opinion date: 21-Mar-2013

[Published Pending EC decisions and European Public Assess ... - Apr 26 2013]

Entities: capecitabine

First reported Apr 18 2013 - Updated Apr 18 2013 - 1 reports

Capecitabine shows promise in pancreatic cancer

Researchers who evaluated three rituximab-containing regimens among patients with follicular lymphoma reported rituximab plus cyclophosphamide,...More » ... [Published Hemonctoday - Apr 18 2013]

Entities: capecitabine, Pancreatic Cancer, cyclophosphamide

First reported Apr 17 2013 - Updated Apr 17 2013 - 1 reports

Investigators from Royal Marsden Hospital Report New Data on. . .

Investigators from Royal Marsden Hospital Report New Data on Pancreatic CancerPancreatic CancerNewsRx.comBy a News Reporter-Staff News Editor at Cancer Weekly -- Fresh data on Pancreatic Cancer are presented in a new report. According to news reporting ... [Published Equities.com - Apr 17 2013]

Entities: Royal Marsden Hospital, Pancreatic Cancer, capecitabine, gemcitabine

First reported Apr 15 2013 - Updated Apr 15 2013 - 1 reports

Phase II trial of preoperative radiochemotherapy with concurrent bevacizumab, capecitabine and ...

Preoperative radiochemotherapy (RCT) with 5-FU or capecitabine is the standard of care for patients with locally advanced rectal cancer (LARC). Preoperative RCT achieves pathological complete response rates (pCR) of 10-15%.We conducted a single arm phase ... [Published 7thSpace - Apr 15 2013]

Entities: capecitabine, bevacizumab, oxaliplatin, Phase II

Quotes

"At the Royal Marsden, the chemotherapy regimes tend to be quite uniform," Dr. Slesser replied. "Generally, all patients are on capecitabine [Xeloda] and oxaliplatin, with a monoclonal agent such as bevacizumab [Avastin]. They tend to get that when they have neoadjuvant chemotherapy."

Primary tumor resection is linked to growth of CRC liver metastases [Published Oncology Report - May 23 2013]

Yet other sequencing methods are disclosed, e g., in U S Pat. No. 5,580,732 entitled "Method of DNA Sequencing Employing A Mixed DNA-Polymer Chain Probe" and U S Pat. No. 5,571,676 entitled "Method For Mismatch-Directed In Vitro DNA Sequencing."

Gene polymorphisms predictive for dual TKI therapy [Published PharmCast - May 23 2013]

According to the news editors, the research concluded: "Future studies should assess newly approved agents and the impact of coverage decisions for these agents under the Medicare Part D program."

Study Data from University of North Carolina Update Knowledg. . . [Published Equities.com - May 23 2013]

...every treatment at every patient, we could make intelligent decisions and say, "this is a therapy that has a high probability of success" and "this is a therapy that for all practical purposes will not be useful" and make treatment decisions on that basis...

Colorectal Cancer Treatments and Therapy Innovations [Published Cancernetwork.com - May 22 2013]

More Content

sort by: Date \| Relevance
Adherex urged to consider larger eniluracil trials [Published Stockwatch - 20 hours ago]
Adherex Reports Feedback from the FDA from End ... [Published Market Wire - 20 hours ago]
Adherex Reports Feedback from the FDA from End ... [Published Marketwire - Breaking News Releases - 20 hours ago]
Primary tumor resection is linked to growth of ... [Published Oncology Report - May 23 2013]
Gene polymorphisms predictive for dual TKI therapy [Published PharmCast - May 23 2013]
Study Data from University of North Carolina Up... [Published Equities.com - May 23 2013]
Colorectal Cancer Treatments and Therapy Innova... [Published Cancernetwork.com - May 22 2013]
Incyte Corporation CEO Presents at UBS Global H... [Published Seeking Alpha - May 20 2013]
Eisai files application with EMA for indication... [Published Individual.com - May 20 2013]
ZELTIA SA: PharmaMar commences a Phase Ib trial... [Published 4 Traders - May 20 2013]
Biomarker Analysis Identifies Women Most Likely... [Published CancerConnect.com - May 20 2013]
How Do I Treat Patients with Locally Advanced G... [Published Oncology Times - May 18 2013]
Study Findings from G. Bisagni et al Broaden Un... [Published NewsRX - May 17 2013]
New Medical Oncology Study Findings Recently We... [Published NewsRX - May 17 2013]
EISAI TO PRESENT NEW RESEARCH ON ONCOLOGY PRODU... [Published Noodls - May 17 2013]
Eisai Highlights New Research On Melanoma, Brea... [Published Yahoo! Finance - May 16 2013]
Eisai Highlights New Research On Melanoma, Brea... [Published Zecco - May 16 2013]
Human medicines European Public Assessment Repo... [Published Pending EC decisions and European Public Assess ... - May 14 2013]
Celldex Therapeutics' Management Presents at Cr... [Published Seeking Alpha - May 11 2013]
Incyte Reports First-Quarter 2013 Financial Res... [Published Equities.com - May 08 2013]
Study: FOLFIRINOX Followed by Chemoradiation Sh... [Published Bio-Medicine - May 08 2013]
Study: FOLFIRINOX Followed by Chemoradiation Sh... [Published PRWeb - May 08 2013]
Onyx Pharmaceuticals Management Discusses Q1 20... [Published Seeking Alpha - May 08 2013]
Eisai beantragt zulassung für frühere anwendung... [Published PR Newswire - May 07 2013]
Eisai solicita autorización para un uso más tem... [Published PR Newswire - May 07 2013]
Eisai richiede l'autorizzazione per l'uso preco... [Published PR Newswire - May 07 2013]
Eisai Files for Earlier use of Halaven (Eribuli... [Published FinanzNachrichten.de - May 07 2013]
Human medicines European Public Assessment Repo... [Published Pending EC decisions and European Public Assess ... - May 06 2013]
Anti-HER2 Therapy May Obviate Need for Chemothe... [Published Oncology Times - May 04 2013]
Market Report, "Neuroendocrine Tumors - Pipelin... [Published Live-PR.com - May 02 2013]